.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,854,290

« Back to Dashboard

Claims for Patent: 5,854,290

Title: Use of guanfacine in the treatment of behavioral disorders
Abstract:Disclosed is a method of treating disorders which have prominent symptoms of behavioral disinhibition (e.g., Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, or the disinhibitory symptoms accompanying Post-traumatic Stress Disorder or dementia) in a primate with minimal sedative side effects by administering thereto a therapeutically effective amount of guanfacine.
Inventor(s): Arnsten; Amy F. T. (Bethany, CT), Goldman-Rakic; Patricia S. (New Haven, CT), Hunt; Robert H. (Nashville, TN)
Assignee: Arnsten; Amy F. T. (Bethany, CT) Goldman-Rakic; Patricia (New Haven, CT) Hunt; Robert H. (Nashville, TN)
Application Number:08/531,643
Patent Claims: 1. A method of treating a behavioral disinhibition in a primate without inducing excessive sedation, comprising

administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight.

2. The method of claim 1, comprising the additional step of readministering the dose at an interval required to obtain a desired level and duration of behavioral inhibition.

3. The method of claim 1, wherein the primate is a rhesus monkey.

4. The method of claim 1, wherein the primate is a human.

5. The method of claim 4, wherein the dose ranges between about 0.03 mg/kg of body weight and about 0.25 mg/kg of body weight.

6. The method of claim 1, wherein the behavioral disinhibition is one of Attention-Deficit Hyperactivity Disorder, Conduct Disorder, Oppositional-Defiant Disorder, Tourette's Syndrome, Lesch-Nyhan Syndrome, Post-Traumatic Stress Disorder and dementia.

7. A method of inhibiting a disinhibitory behavior in a primate without inducing excessive sedation, comprising:

administering to the primate a behavior inhibiting dose of guanfacine, wherein the dose ranges between 0.01 mg/kg of body weight and 0.86 mg/kg of body weight.

8. The method of claim 7, comprising the additional step of readministering the dose at an interval required to obtain a desired level and duration of behavioral inhibition.

9. The method of claim 7, wherein the primate is a rhesus monkey.

10. The method of claim 7, wherein the primate is a human.

11. The method of claim 10, wherein the dose ranges between about 0.03 mg/kg of body weight and about 0.25 mg/kg of body weight.

12. The method of claim 7, wherein the behavior is one of hyperactivity, agitation, impulsivity, aggression, inattention, distractibility, disorganization, uncontrolled movements, and self-mutilation.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc